270 related articles for article (PubMed ID: 23064471)
1. The prolactin receptor mediates HOXA1-stimulated oncogenicity in mammary carcinoma cells.
Hou L; Xu B; Mohankumar KM; Goffin V; Perry JK; Lobie PE; Liu DX
Int J Oncol; 2012 Dec; 41(6):2285-95. PubMed ID: 23064471
[TBL] [Abstract][Full Text] [Related]
2. HOXA1-stimulated oncogenicity is mediated by selective upregulation of components of the p44/42 MAP kinase pathway in human mammary carcinoma cells.
Mohankumar KM; Xu XQ; Zhu T; Kannan N; Miller LD; Liu ET; Gluckman PD; Sukumar S; Emerald BS; Lobie PE
Oncogene; 2007 Jun; 26(27):3998-4008. PubMed ID: 17213808
[TBL] [Abstract][Full Text] [Related]
3. Transcriptional activation of signal transducer and activator of transcription (STAT) 3 and STAT5B partially mediate homeobox A1-stimulated oncogenic transformation of the immortalized human mammary epithelial cell.
Mohankumar KM; Perry JK; Kannan N; Kohno K; Gluckman PD; Emerald BS; Lobie PE
Endocrinology; 2008 May; 149(5):2219-29. PubMed ID: 18276758
[TBL] [Abstract][Full Text] [Related]
4. CAML promotes prolactin-dependent proliferation of breast cancer cells by facilitating prolactin receptor signaling pathways.
Lim JH; Kim TY; Kim WH; Park JW
Breast Cancer Res Treat; 2011 Nov; 130(1):19-27. PubMed ID: 21128111
[TBL] [Abstract][Full Text] [Related]
5. Endogenous human prolactin and not exogenous human prolactin induces estrogen receptor alpha and prolactin receptor expression and increases estrogen responsiveness in breast cancer cells.
Gutzman JH; Miller KK; Schuler LA
J Steroid Biochem Mol Biol; 2004 Jan; 88(1):69-77. PubMed ID: 15026085
[TBL] [Abstract][Full Text] [Related]
6. Human prolactin (hPRL) antagonists inhibit hPRL-activated signaling pathways involved in breast cancer cell proliferation.
Llovera M; Pichard C; Bernichtein S; Jeay S; Touraine P; Kelly PA; Goffin V
Oncogene; 2000 Sep; 19(41):4695-705. PubMed ID: 11032019
[TBL] [Abstract][Full Text] [Related]
7. Zinc Finger Homeodomain Factor Zfhx3 Is Essential for Mammary Lactogenic Differentiation by Maintaining Prolactin Signaling Activity.
Zhao D; Ma G; Zhang X; He Y; Li M; Han X; Fu L; Dong XY; Nagy T; Zhao Q; Fu L; Dong JT
J Biol Chem; 2016 Jun; 291(24):12809-12820. PubMed ID: 27129249
[TBL] [Abstract][Full Text] [Related]
8. Re-evaluation of the prolactin receptor expression in human breast cancer.
Galsgaard ED; Rasmussen BB; Folkesson CG; Rasmussen LM; Berchtold MW; Christensen L; Panina S
J Endocrinol; 2009 Apr; 201(1):115-28. PubMed ID: 19153125
[TBL] [Abstract][Full Text] [Related]
9. Prolactin induces up-regulation of its cognate receptor in breast cancer cells via transcriptional activation of its generic promoter by cross-talk between ERα and STAT5.
Kavarthapu R; Tsai Morris CH; Dufau ML
Oncotarget; 2014 Oct; 5(19):9079-91. PubMed ID: 25193864
[TBL] [Abstract][Full Text] [Related]
10. Essential role of endogenous prolactin and CDK7 in estrogen-induced upregulation of the prolactin receptor in breast cancer cells.
Kavarthapu R; Dufau ML
Oncotarget; 2017 Apr; 8(16):27353-27363. PubMed ID: 28423697
[TBL] [Abstract][Full Text] [Related]
11. Signal transducer and activator of transcription (STAT)-5A and STAT5B differentially regulate human mammary carcinoma cell behavior.
Tang JZ; Zuo ZH; Kong XJ; Steiner M; Yin Z; Perry JK; Zhu T; Liu DX; Lobie PE
Endocrinology; 2010 Jan; 151(1):43-55. PubMed ID: 19966185
[TBL] [Abstract][Full Text] [Related]
12. EGF stimulates Pit-1 independent transcription of the human prolactin pituitary promoter in human breast cancer SK-BR-3 cells through its proximal AP-1 response element.
Manfroid I; Van de Weerdt C; Baudhuin A; Martial JA; Muller M
Mol Cell Endocrinol; 2005 Jan; 229(1-2):127-39. PubMed ID: 15607537
[TBL] [Abstract][Full Text] [Related]
13. Regulation of prolactin receptor expression by the tumour promoting phorbol ester 12-O-tetradecanoylphorbol-13-acetate in human breast cancer cells.
Ormandy CJ; Lee CS; Kelly PA; Sutherland RL
J Cell Biochem; 1993 May; 52(1):47-56. PubMed ID: 8320275
[TBL] [Abstract][Full Text] [Related]
14. Two wrongs can make a right: dimers of prolactin and growth hormone receptor antagonists behave as agonists.
Langenheim JF; Tan D; Walker AM; Chen WY
Mol Endocrinol; 2006 Mar; 20(3):661-74. PubMed ID: 16269515
[TBL] [Abstract][Full Text] [Related]
15. Transcriptional and spatiotemporal regulation of prolactin receptor mRNA and cooperativity with progesterone receptor function during ductal branch growth in the mammary gland.
Hovey RC; Trott JF; Ginsburg E; Goldhar A; Sasaki MM; Fountain SJ; Sundararajan K; Vonderhaar BK
Dev Dyn; 2001 Oct; 222(2):192-205. PubMed ID: 11668597
[TBL] [Abstract][Full Text] [Related]
16. Role of EGF/ERBB1 in the transcriptional regulation of the prolactin receptor independent of estrogen and prolactin in breast cancer cells.
Kavarthapu R; Dufau ML
Oncotarget; 2016 Oct; 7(40):65602-65613. PubMed ID: 27564112
[TBL] [Abstract][Full Text] [Related]
17. Growth hormone signaling in human T47D breast cancer cells: potential role for a growth hormone receptor-prolactin receptor complex.
Xu J; Zhang Y; Berry PA; Jiang J; Lobie PE; Langenheim JF; Chen WY; Frank SJ
Mol Endocrinol; 2011 Apr; 25(4):597-610. PubMed ID: 21310852
[TBL] [Abstract][Full Text] [Related]
18. Alpha
Castillo LF; Rivero EM; Goffin V; Lüthy IA
Cell Signal; 2017 Jun; 34():76-85. PubMed ID: 28302567
[TBL] [Abstract][Full Text] [Related]
19. HOXA1 is required for E-cadherin-dependent anchorage-independent survival of human mammary carcinoma cells.
Zhang X; Emerald BS; Mukhina S; Mohankumar KM; Kraemer A; Yap AS; Gluckman PD; Lee KO; Lobie PE
J Biol Chem; 2006 Mar; 281(10):6471-81. PubMed ID: 16373333
[TBL] [Abstract][Full Text] [Related]
20. Prolactin, growth hormone, and epidermal growth factor activate Stat5 in different compartments of mammary tissue and exert different and overlapping developmental effects.
Gallego MI; Binart N; Robinson GW; Okagaki R; Coschigano KT; Perry J; Kopchick JJ; Oka T; Kelly PA; Hennighausen L
Dev Biol; 2001 Jan; 229(1):163-75. PubMed ID: 11133161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
